AxoGen (NASDAQ:AXGN) Price Target Raised to $60.00

AxoGen (NASDAQ:AXGN) had its target price raised by Canaccord Genuity Group from $55.00 to $60.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Several other equities analysts have also issued reports on the company. Citigroup restated a “market outperform” rating on shares of AxoGen in a research note on Thursday, July 30th. Raymond James Financial reissued an “outperform” rating and set a $57.00 price objective on shares of AxoGen in a report on Thursday. Jefferies Financial Group restated a “buy” rating and issued a $60.00 target price on shares of AxoGen in a research note on Wednesday. Morgan Stanley lowered AxoGen to a “hold” rating in a research note on Tuesday, September 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AxoGen in a research note on Wednesday, August 26th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AxoGen has a consensus rating of “Moderate Buy” and a consensus price target of $57.92.

AxoGen Stock Performance

NASDAQ AXGN opened at $49.37 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 12.02 and a quick ratio of 5.04. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of -75.95 and a beta of 1.17. The company’s fifty day moving average is $42.86 and its two-hundred day moving average is $39.45. AxoGen has a 52-week low of $21.68 and a 52-week high of $52.91.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.08. The business had revenue of $75.83 million during the quarter, compared to analyst estimates of $73.45 million. AxoGen had a negative net margin of 11.96% and a negative return on equity of 5.35%. Equities research analysts forecast that AxoGen will post -0.44 EPS for the current year.

Insider Buying and Selling at AxoGen

In other AxoGen news, EVP Marc Began sold 67,500 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the completion of the transaction, the executive vice president owned 50,135 shares in the company, valued at $2,373,390.90. This trade represents a 57.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 98,503 shares of company stock worth $4,656,947. 2.44% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AxoGen

Hedge funds have recently modified their holdings of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in shares of AxoGen by 46.0% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 30,150 shares of the medical equipment provider’s stock valued at $1,264,000 after acquiring an additional 9,500 shares during the period. Sterling Capital Management LLC boosted its stake in shares of AxoGen by 858.9% in the 3rd quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider’s stock valued at $74,000 after purchasing an additional 1,589 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of AxoGen by 16.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock worth $118,000 after purchasing an additional 409 shares during the last quarter. Artemis Investment Management LLP grew its holdings in shares of AxoGen by 27.5% in the 3rd quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock worth $74,659,000 after purchasing an additional 384,200 shares during the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of AxoGen in the 2nd quarter worth about $272,000. 80.29% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Strong Q3 execution and higher guidance: AxoGen reported 26% revenue growth and 45% adjusted EBITDA growth for the third quarter of 2026. Management maintained a target of at least $290 million in 2026 sales and expects gross margin of 73% or higher, reinforcing the company’s growth and operating-leverage story. AxoGen Third-Quarter Earnings Results
• Positive Sentiment: Analysts raised their targets: Canaccord Genuity increased its price target to $60 from $55 and maintained a Buy rating. Truist also raised its target to $60 from $53, while Wells Fargo increased its target to $56 from $48 and kept an Overweight rating. HC Wainwright lifted its target to $56 from $53 and retained a Buy rating. These revisions indicate improving confidence in AxoGen’s earnings outlook. Truist AxoGen Price Target Update
• Positive Sentiment: BioCircuit acquisition expands the opportunity: An investment analysis characterized AxoGen as evolving toward a leading procedural platform in peripheral nerve repair. The planned $200 million BioCircuit, or NerveTape, acquisition is intended to reduce technical barriers for surgeons, broaden the addressable market and be accretive at an estimated 5.9 times 2027 sales. AxoGen Taking the Friction Out of Nerve Repair
• Neutral Sentiment: Valuation remains an investor debate: Coverage is focused on whether AXGN’s growth prospects justify its elevated valuation after its substantial advance. The stock’s performance relative to other medical companies may attract momentum investors, but also raises the risk that much of the near-term optimism is already reflected in the share price. Does AxoGen Have More Upside?
• Negative Sentiment: Profitability and execution risks remain: Despite improving adjusted EBITDA, AxoGen continues to report negative net income and analysts expect a full-year loss. Investors must also weigh acquisition integration, dilution and the company’s premium valuation against the possibility of slower growth.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.